View Post

Improving Accuracy in Predicting Response to Neoadjuvant Treatment in Patients With Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Danielle Garcia From: oncozine.com A liquid biopsy, a sampling and analysis of non-solid biological tissue, primarily blood, is mainly used as a diagnostic and monitoring tool for diseases such as cancer. One of the benefits of liquid biopsies is that they are largely non-invasive. Another advantage is that liquid biopsies may potentially help detect, characterize, and monitor cancers earlier …

View Post

Addition of SDX-7320 to Palbociclib Inhibits Tumor Growth in Breast Cancer Xenografts

In Clinical Studies News by Barbara Jacoby

By: Hayley Virgil From: onclive.com The addition of SDX-7320, a novel inhibitor of methionine aminopeptidase 2 (MetAP2), to palbociclib (Ibrance) was found to inhibit MCF-7 tumor growth and reduce the expression of proteins associated with resistance to palbociclib, according to data from a study virtually presented during the AACR Annual Meeting 2021.1 Results indicated that SDX-7320 and palbociclib, when given …

View Post

Contrast-Enhanced Mammography Useful in Women with Breast Implants

In Clinical Studies News by Barbara Jacoby

By: Whitney J. Palmer From: diagnosticimaging.com CEM performance showed no significant difference between women with or without breast implants, and it produced very few complications. Contrast-enhanced mammography (CEM) is an acceptable alternative to breast MRI for women who have breast implants, according to recently presented research. CEM has already been shown to be an effective diagnostic or screening option for …

View Post

Gedatolisib Plus Palbociclib Shows Promise in Treating ER+/HER2- Advanced Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Sara Karlovitch From: targetedonc.com Gedatolisib, a first-in-class PI3K/mTOR inhibitor, plus palbociclib and endocrine therapy demonstrated tolerability and preliminary efficacy in patients with ER+/HER2- advanced or metastatic breast cancer. Gedatolisib, a first-in-class PI3K/mTOR inhibitor, plus palbociclib (Ibrance) and endocrine therapy demonstrated tolerability and preliminary efficacy in patients with ER+/HER2- advanced or metastatic breast cancer, according to early results on a …

View Post

First-Line Palbociclib/Letrozole Shows Real-World Survival Benefit in HR+ Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Kristi Rosa From: onclive.com Palbociclib in combination with endocrine therapy resulted in improved survival outcomes in a real-world population of patients with hormone receptor–positive, HER2-negative, metastatic breast cancer vs letrozole alone in the first-line setting. Palbociclib (Ibrance) in combination with endocrine therapy resulted in improved survival outcomes in a real-world population of patients with hormone receptor (HR)–positive, HER2-negative, metastatic …

View Post

Real-World Evidence Supports Efficacy of Palbociclib Plus Letrozole in HR+/HER2– Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Audrey Sternberg From: cancernetwork.com An analysis of real-world outcomes in a cohort of patients treated in mostly community settings showed that palbociclib plus letrozole improved both progression-free and overall survival in women with hormone receptor–positive, HER2-negative metastatic breast cancer. Data published in Breast Cancer Research showed real-world efficacy of palbociclib (Ibrance) in combination with letrozole in women with hormone …

View Post

Treating aggressive breast cancer with an anti-diabetic drug

In Clinical Studies News by Barbara Jacoby

By: National University of Singapore From: medicalxpress.com National University of Singapore researchers developed an approach to target highly resistant triple-negative breast cancers (TNBCs) by interfering with their energy production using cytotoxic gold-metformin prodrugs. Metformin is a widely prescribed “over-the-counter” medication for Type 2 diabetes. There is some evidence that patients taking metformin for a long time have significantly reduced risk …

View Post

FDA Grants Regular Approval to Sacituzumab Govitecan for TNBC

In Clinical Studies News by Barbara Jacoby

From: onclive.com The FDA has granted a regular approval to sacituzumab govitecan (Trodelvy) for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have previously received 2 or more systemic therapies, at least 1 of them for metastatic disease. The Trop2-directed antibody and topoisomerase inhibitor drug conjugate was previously granted an accelerated approval in …

View Post

Parkinson’s, cancer, type 2 diabetes share a key element that drives disease

In Clinical Studies News by Barbara Jacoby

Source: Salk Institute for Biological Studies From: prnewswire.com Enzyme with central role in cancer and type 2 diabetes also activates “clean-up” protein in Parkinson’s When cells are stressed, chemical alarms go off, setting in motion a flurry of activity that protects the cell’s most important players. During the rush, a protein called Parkin hurries to protect the mitochondria, the power …

View Post

Breast Cancer Survivors’ Fear of Cancer Returning Linked to Genomic Test Results, Psychological Factors

In Clinical Studies News by Barbara Jacoby

From: nyu.edu Modifiable Factors Such as Anxiety and Emotional Response to Cancer Are Strongest Predictors of Fear Breast cancer survivors with a higher risk of cancer recurrence based on genomic testing may experience greater fear of their cancer returning, according to a new study led by researchers at NYU Rory Meyers College of Nursing. However, psychological factors such as anxiety …